Glioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imaging and Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging

References

1. ↵
   Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450–459

   PubMedWeb of Science
2. ↵
   Brant-Zawadzki M, Berry I, Osaki L, et al. Gd-DTPA in clinical MR of the brain: I. Intraaxial lesions. AJR Am J Roentgenol 1986;147:1223–1230

   PubMed
3. Brant-Zawadzki M, Badami JP, Mills CM, et al. Primary intracranial tumor imaging: a comparison of magnetic resonance and CT. Radiology 1984;150:435–440

   PubMedWeb of Science
4. Bydder GM, Steiner RE, Young IR, et al. Clinical NMR imaging of the brain: 140 cases. AJR Am J Roentgenol 1982;139:215–236

   CrossRefPubMedWeb of Science
5. Just M, Thelen M. Tissue characterization with T1, T2, and proton density values: results in 160 patients with brain tumors. Radiology 1988;169:779–785

   PubMedWeb of Science
6. ↵
   Felix R, Schorner W, Laniado M, et al. Brain tumors: MR imaging with gadolinium-DTPA. Radiology 1985;156:681–688

   PubMedWeb of Science
7. ↵
   Moller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371–381

   CrossRefPubMedWeb of Science
8. ↵
   Dean BL, Drayer BP, Bird CR, et al. Gliomas: classification with MR imaging. Radiology 1990;174:411–415

   CrossRefPubMedWeb of Science
9. ↵
   Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992;34:463–469

   CrossRefPubMedWeb of Science
10. ↵
    Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993;79:533–536

    PubMedWeb of Science
11. ↵
    Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–798

    CrossRefPubMedWeb of Science
12. ↵
    Ginsberg LE, Fuller GN, Hashmi M, et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436–440

    CrossRefPubMedWeb of Science
13. ↵
    Daumas-Duport C, Scheithauer B, O’Fallon J, et al. Grading of astrocytomas: a simple and reproducible method. Cancer 1988;62:2152–2165

    CrossRefPubMedWeb of Science
14. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985;56:1106–1111

    CrossRefPubMedWeb of Science
15. ↵
    Burger P. Malignant astrocytic neoplasms: classification, pathology, anatomy, and response to therapy. Semin Oncol 1986;13:16–20

    PubMed
16. ↵
    Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

    PubMedWeb of Science
17. Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 1996;17:831–840

    Abstract
18. ↵
    Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479–1486

    CrossRefPubMedWeb of Science
19. Sugahara T, Korogi Y, Shigematsu Y, et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 1999;10:114–124

    PubMed
20. Wong ET, Jackson EF, Hess KR, et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 1998;50:777–781

    Abstract/FREE Full Text
21. Wong JC, Provenzale JM, Petrella JR. Perfusion MR imaging of brain neoplasms. Am J Roentgenol 2000;174:1147–1157

    PubMed
22. ↵
    Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
23. ↵
    Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 1999;9:309–331

    PubMedWeb of Science
24. ↵
    Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. Am J Roentgenol 2002;179:783–789

    CrossRefPubMed
25. ↵
    Petrella JR, Provenzale JM. MR perfusion imaging of the brain: techniques and applications. Am J Roentgenol 2000;175:207–219

    CrossRefPubMedWeb of Science
26. ↵
    Adamson AJ, Rand SD, Prost RW, et al. Focal brain lesions: effect of single-voxel proton MR spectroscopic findings on treatment decisions. Radiology 1998;209:73–78

    PubMed
27. ↵
    Alger JR, Frank JA, Bizzi A, et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990;177:633–641

    PubMedWeb of Science
28. Arnold DL, Shoubridge EA, Villemure JG, et al. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo: preliminary observations on tumor grading. NMR Biomed 1990;3:184–189

    PubMed
29. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989;172:541–548

    PubMedWeb of Science
30. Castillo M, Kwock L. Clinical applications of proton magnetic resonance spectroscopy in the evaluation of common intracranial tumors. Top Magn Reson Imaging 1999;10:104–113

    PubMed
31. ↵
    Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000;21:1645–1649

    Abstract/FREE Full Text
32. Chang L, McBride D, Miller BL, et al. Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimaging 1995;5:157–163

    PubMed
33. Cheng LL, Chang IW, Louis DN, et al. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 1998;58:1825–1832

    Abstract/FREE Full Text
34. Danielson ER, Ross BD. Magnetic Resonance Spectroscopy of Neurological Diseases. New York, NY: Marcel Dekker Inc.,1998
35. ↵
    Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001;22:604–612

    Abstract/FREE Full Text
36. Falini A, Calabrese G, Origgi D, et al. Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives. J Neurol 1996;243:706–714

    CrossRefPubMedWeb of Science
37. Fountas KN, Kapsalaki EZ, Gotsis SD, et al. In vivo proton magnetic resonance spectroscopy of brain tumors. Stereotact Funct Neurosurg 2000;74:83–94

    CrossRefPubMed
38. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992;185:675–686

    PubMed
39. Kaminogo M, Ishimaru H, Morikawa M, et al. Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 2001;43:353–363

    CrossRefPubMedWeb of Science
40. Kugel H, Heindel W, Ernestus RI, et al. Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 1992;183:701–709

    PubMedWeb of Science
41. Butzen J, Prost R, Chetty V, et al. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. AJNR Am J Neuroradiol 2000;21:1213–1219

    Abstract/FREE Full Text
42. Luyten PR, Marien AJ, Heindel W, et al. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 1990;176:791–799

    PubMedWeb of Science
43. McBride DQ, Miller BL, Nikas DL, et al. Analysis of brain tumors using 1H magnetic resonance spectroscopy. Surg Neurol 1995;44:137–144

    CrossRefPubMedWeb of Science
44. McKnight TR, Noworolski SM, Vigneron DB, et al. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J Magn Reson Imaging 2001;13:167–177

    CrossRefPubMedWeb of Science
45. ↵
    Meyerand ME, Pipas JM, Mamourian A, et al. Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol 1999;20:117–123

    Abstract/FREE Full Text
46. Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996;84:449–458

    CrossRefPubMedWeb of Science
47. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med 2001;46:228–239

    CrossRefPubMedWeb of Science
48. Ott D, Hennig J, Ernst T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 1993;186:745–752

    PubMedWeb of Science
49. ↵
    Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593–1603

    Abstract
50. ↵
    Preul MC, Caramanos Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996;2:323–325

    CrossRefPubMedWeb of Science
51. Rand SD, Prost R, Haughton V, et al. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 1997;18:1695–1704

    Abstract
52. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 1994;10:191–247

    PubMedWeb of Science
53. Rutter A, Hugenholtz H, Saunders JK, et al. Classification of brain tumors by ex vivo 1H NMR spectroscopy. J Neurochem 1995;64:1655–1661

    PubMedWeb of Science
54. ↵
    Shimizu H, Kumabe T, Tominaga T, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17:737–747

    Abstract
55. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997;87:516–524

    PubMedWeb of Science
56. ↵
    Wilken B, Dechent P, Herms J, et al. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr Neurol 2000;23:22–31

    CrossRefPubMed
57. ↵
    Tamiya T, Kinoshita K, Ono Y, et al. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 2000;42:333–338

    CrossRefPubMed
58. ↵
    Shimizu H, Kumabe T, Shirane R, et al. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 2000;21:659–665

    Abstract/FREE Full Text
59. ↵
    Yang D, Korogi Y, Sugahara T, et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002;44:656–666

    CrossRefPubMed
60. ↵
    Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222:715–721

    PubMedWeb of Science
61. ↵
    Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 2000;21:357–366

    Abstract/FREE Full Text
62. ↵
    Tzika AA, Vajapeyam S, Barnes PD. Multivoxel proton MR spectroscopy and hemodynamic MR imaging of childhood brain tumors: preliminary observations. AJNR Am J Neuroradiol 1997;18:203–218

    Abstract
63. ↵
    Lev MH. Gliomatosis cerebri has normal relative blood volume: really?! Who cares? Should you? AJNR Am J Neuroradiol 2002;23:345–346

    FREE Full Text
64. ↵
    Ringertz J. Grading of gliomas. Acta Pathol Microbiol Scand 1950;27:51–64

    PubMedWeb of Science
65. ↵
    Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803

    CrossRefPubMedWeb of Science
66. ↵
    Lin AP, Ross BD. Short-echo time proton MR spectroscopy in the presence of gadolinium. J Comput Assist Tomogr 2001;25:705–712

    CrossRefPubMed
67. Murphy PS, Dzik-Jurasz AS, Leach MO, et al. The effect of Gd-DTPA on T1-weighted choline signal in human brain tumours. Magn Reson Imaging 2002;20:127–130

    CrossRefPubMed
68. ↵
    Smith JK, Kwock L, Castillo M. Effects of contrast material on single-volume proton MR spectroscopy. AJNR Am J Neuroradiol 2000;21:1084–1089

    Abstract/FREE Full Text
69. ↵
    Tate AR, Majos C, Moreno A, et al. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003;49:29–36

    CrossRefPubMedWeb of Science
70. ↵
    Nelson JS, Tsukada Y, Schoenfeld D, et al. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983;52:550–554

    CrossRefPubMedWeb of Science
71. ↵
    Li X, Lu Y, Pirzkall A, et al. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging 2002;16:229–237

    CrossRefPubMedWeb of Science
72. ↵
    Carpinelli G, Carapella CM, Palombi L, et al. Differentiation of glioblastoma multiforme from astrocytomas by in vitro 1H MRS analysis of human brain tumors. Anticancer Res 1996;16:1559–1563

    PubMedWeb of Science
73. ↵
    McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002;97:794–802

    PubMedWeb of Science
74. ↵
    Isobe T, Matsumura A, Anno I, et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 2002;20:343–349

    CrossRefPubMed
75. ↵
    Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881–890

    Abstract/FREE Full Text
76. Nelson SJ, Huhn S, Vigneron DB, et al. Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. J Magn Reson Imaging 1997;7:1146–1152

    PubMed
77. ↵
    Nelson SJ, Vigneron DB, Dillon WP. Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 1999;12:123–138

    CrossRefPubMed